Trial
NCT03552380
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Roberto Pili
Collaborators
Bristol-Myers Squibb; Syndax Pharmaceuticals; Indiana University
Condition
Renal Cell Carcinoma
Intervention
Entinostat
Why stopped
Funder halted development of compound in this disease
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-03